B-intervention	0	16	Hypofractionated
I-intervention	17	26	radiation
O	27	36	treatment
O	37	46	following
O	47	57	mastectomy
O	58	60	in
O	61	66	early
O	67	73	breast
O	74	80	cancer
O	80	81	:
O	82	85	the
O	86	98	Christchurch
O	99	109	experience
O	109	110	.

O	111	119	Although
O	120	136	hypofractionated
O	137	149	radiotherapy
O	150	151	(
O	151	155	HFRT
O	155	156	)
O	157	160	has
O	161	167	become
O	168	170	an
O	171	179	accepted
O	180	186	option
O	187	190	for
O	191	196	whole
O	196	197	-
O	197	203	breast
O	204	215	irradiation
O	216	221	after
O	222	228	breast
O	228	229	-
O	229	239	conserving
O	240	247	surgery
O	247	248	,
O	249	254	there
O	255	257	is
O	258	265	limited
O	266	274	evidence
O	275	277	to
O	278	285	support
O	286	290	HFRT
O	291	293	to
O	294	297	the
O	298	303	chest
O	304	308	wall
O	309	318	following
O	319	329	mastectomy
O	329	330	.

O	331	333	We
O	334	349	retrospectively
O	350	358	analysed
O	359	363	post
O	363	364	-
O	364	374	mastectomy
O	375	383	patients
O	384	391	treated
O	392	396	with
O	397	401	HFRT
O	402	404	in
O	405	417	Christchurch
O	418	420	to
O	421	430	determine
O	431	438	whether
O	439	443	HFRT
O	444	450	yields
O	451	461	acceptable
O	462	470	efficacy
O	471	474	and
O	475	483	toxicity
O	483	484	.

O	485	488	The
O	489	501	Christchurch
O	502	510	oncology
O	511	519	database
O	520	523	was
O	524	528	used
O	529	531	to
O	532	540	identify
O	541	547	breast
O	548	554	cancer
O	555	563	patients
O	564	571	treated
O	572	576	with
O	577	585	adjuvant
O	586	590	HFRT
O	591	593	to
O	594	597	the
O	598	603	chest
O	604	608	wall
O	609	618	following
O	619	620	a
O	621	631	mastectomy
O	632	639	between
O	640	644	2003
O	645	648	and
O	649	653	2008
O	653	654	.

O	655	663	Eligible
B-eligibility	664	668	post
I-eligibility	668	669	-
I-eligibility	669	679	mastectomy
I-eligibility	680	688	patients
O	689	693	were
O	694	701	treated
O	702	706	with
O	707	709	40
O	710	712	Gy
O	713	715	in
O	716	718	16
O	719	724	daily
O	725	734	fractions
O	734	735	.

O	736	745	Treatment
O	746	754	outcomes
O	755	763	assessed
O	764	772	included
O	773	778	local
O	779	789	recurrence
O	789	790	-
O	790	794	free
O	795	803	survival
O	803	804	,
O	805	811	breast
O	812	818	cancer
O	819	827	survival
O	827	828	,
O	829	836	overall
O	837	845	survival
O	846	849	and
O	850	855	acute
O	856	866	toxicities
O	866	867	.

B-total-participants	868	871	One
I-total-participants	872	879	hundred
I-total-participants	880	886	thirty
I-total-participants	886	887	-
I-total-participants	887	892	three
O	893	901	patients
O	902	906	were
O	907	917	identified
O	917	918	.

O	919	922	The
O	923	929	median
O	930	936	follow
O	936	937	-
O	937	939	up
O	940	946	period
O	947	950	was
O	951	952	5
O	952	953	.
O	953	955	03
O	956	961	years
O	961	962	.

B-iv-bin-abs	963	968	Three
O	969	977	patients
O	978	981	had
O	982	983	a
B-outcome	984	989	local
I-outcome	990	1000	recurrence
O	1001	1003	as
O	1004	1005	a
O	1006	1011	first
O	1012	1017	event
O	1017	1018	,
O	1019	1028	resulting
O	1029	1031	in
B-outcome	1032	1033	5
I-outcome	1033	1034	-
I-outcome	1034	1038	year
I-outcome	1039	1044	local
I-outcome	1045	1055	recurrence
I-outcome	1055	1056	-
I-outcome	1056	1060	free
I-outcome	1061	1069	survival
O	1070	1072	of
B-iv-bin-percent	1073	1075	97
I-iv-bin-percent	1075	1076	.
I-iv-bin-percent	1076	1077	6
I-iv-bin-percent	1077	1078	%
O	1078	1079	.

B-outcome	1080	1084	Five
I-outcome	1084	1085	-
I-outcome	1085	1089	year
I-outcome	1090	1097	overall
I-outcome	1098	1106	survival
O	1107	1110	and
B-outcome	1111	1112	5
I-outcome	1112	1113	-
I-outcome	1113	1117	year
I-outcome	1118	1124	breast
I-outcome	1125	1131	cancer
I-outcome	1132	1140	survival
O	1141	1145	were
B-iv-bin-percent	1146	1148	74
I-iv-bin-percent	1148	1149	.
I-iv-bin-percent	1149	1150	7
I-iv-bin-percent	1150	1151	%
O	1152	1155	and
B-iv-bin-percent	1156	1158	77
I-iv-bin-percent	1158	1159	.
I-iv-bin-percent	1159	1160	7
I-iv-bin-percent	1160	1161	%
O	1161	1162	,
O	1163	1175	respectively
O	1175	1176	.

O	1177	1180	The
O	1181	1194	prospectively
O	1195	1203	assessed
B-outcome	1204	1209	acute
I-outcome	1210	1220	toxicities
O	1221	1225	were
O	1226	1232	mostly
O	1233	1238	grade
O	1239	1240	1
O	1240	1241	.

O	1242	1244	In
O	1245	1255	particular
O	1255	1256	,
O	1257	1260	the
O	1261	1270	incidence
O	1271	1273	of
B-outcome	1274	1279	grade
I-outcome	1280	1281	2
I-outcome	1282	1286	skin
I-outcome	1287	1295	toxicity
O	1296	1299	was
B-iv-bin-percent	1300	1302	10
I-iv-bin-percent	1302	1303	.
I-iv-bin-percent	1303	1304	7
I-iv-bin-percent	1304	1305	%
O	1305	1306	,
O	1307	1310	and
B-iv-bin-abs	1311	1313	no
O	1314	1322	patients
O	1323	1334	experienced
B-outcome	1335	1340	grade
I-outcome	1341	1342	3
I-outcome	1343	1347	skin
I-outcome	1348	1356	toxicity
O	1356	1357	.

O	1358	1361	The
O	1362	1366	high
O	1367	1372	local
O	1373	1380	control
O	1381	1385	rate
O	1386	1390	with
O	1391	1395	HFRT
O	1395	1396	,
O	1397	1405	combined
O	1406	1410	with
O	1411	1421	acceptable
O	1422	1430	toxicity
O	1431	1434	and
O	1435	1438	the
O	1439	1448	practical
O	1449	1457	benefits
O	1458	1460	of
O	1461	1462	a
O	1463	1470	shorter
O	1471	1480	treatment
O	1481	1485	time
O	1485	1486	,
O	1487	1495	supports
O	1496	1499	its
O	1500	1507	ongoing
O	1508	1511	use
O	1512	1514	in
O	1515	1518	the
O	1519	1527	eligible
O	1528	1535	patient
O	1536	1541	group
O	1541	1542	.

O	1543	1544	A
O	1545	1555	randomised
O	1556	1566	controlled
O	1567	1572	trial
O	1573	1578	would
O	1579	1581	be
O	1582	1591	necessary
O	1592	1594	to
O	1595	1599	more
O	1600	1610	completely
O	1611	1617	assess
O	1618	1621	the
O	1622	1627	acute
O	1628	1631	and
O	1632	1636	long
O	1636	1637	-
O	1637	1641	term
O	1642	1650	toxicity
O	1651	1653	of
O	1654	1658	HFRT
O	1659	1667	compared
O	1668	1672	with
O	1673	1681	standard
O	1682	1695	fractionation
O	1695	1696	.
